Attached files
| file | filename |
|---|---|
| EX-99 - MICROBOT POWERPOINT PRESENTATION - Microbot Medical Inc. | exhibit99.htm |
|
UNITED STATES
|
|
SECURITIES AND EXCHANGE COMMISSION
|
|
Washington, D.C. 20549
|
|
FORM 8-K
|
|
CURRENT REPORT
|
|
PURSUANT TO SECTION 13 OR 15(d) OF THE
|
|
SECURITIES EXCHANGE ACT OF 1934
|
|
Date of report (Date of earliest event reported): December 19, 2016
|
|
MICROBOT MEDICAL INC.
|
|
(Exact Name of Registrant as Specified in Charter)
|
|
Delaware
|
000-19871
|
94-3078125
|
||||
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission
File Number)
|
(I.R.S. Employer
Identification No.)
|
||||
|
5 HaMada St.,
|
||||||
|
Yokneam 2069204, Israel
|
||||||
|
(Address of Principal Executive Offices) (Zip Code)
|
||||||
|
Registrant’s telephone number, including area code: +972-4-8200-710
|
||||||
|
StemCells, Inc.
|
||||||
|
39899 Balentine Drive, Suite 200
|
||||||
|
Newark, CA 94560
|
||||||
|
(Former Name or Former Address, if Changed Since Last Report)
|
||||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Item 7.01
|
Regulation FD Disclosure
|
Microbot Medical Inc. (the “Registrant”) is furnishing presentation materials included as Exhibit 99.1 to this report pursuant to Item 7.01 of Form 8-K. The Registrant is not undertaking to update this presentation. The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information herein (including Exhibit 99.1).
|
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits
|
Exhibit
Number
|
Description
|
|
|
99.1
|
|
Presentation Materials
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
MICROBOT MEDICAL INC.
|
||||
|
By:
|
/s/ Harel Gadot
|
|||
|
Harel Gadot
Chairman and Chief Executive Officer
|
||||
Date: December 19, 2016